初诊ⅳb期胸段食管鳞癌预后分析及治疗模式探讨

《初诊ⅳb期胸段食管鳞癌预后分析及治疗模式探讨》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153527中国图书分类号R735.1HebeiMedicalUniversity硕士学位论文专业学位初诊ⅣB期胸段食管鳞癌预后分析及治疗模式探讨研究生：王雪锋导师：王军教授专业：肿瘤学二级学院：河北医科大学第四医院2018年3月目录中文摘要············································································································1英文摘要················

2、····························································································3英文缩写············································································································6研究论文初诊ⅣB期胸段食管鳞癌预后分析及治疗模式探讨前言···································

3、·········································································7材料与方法································································································8结果···························································································

4、···············10附图··········································································································14附表··········································································································20讨论······························

5、············································································31结论··········································································································40参考文献·············································································

6、·····················41综述初诊转移性食管癌（ⅣB期）研究进展·················································47致谢··················································································································63个人简历······················································

7、····················································64中文摘要初诊ⅣB期胸段食管鳞癌预后分析及治疗模式探讨摘要目的：分析初诊ⅣB期胸段食管鳞癌患者临床特征、近期疗效、治疗毒副作用，分析预后相关因素并探讨其治疗策略。方法：选取2010-1-1至2016-12-31期间，于河北医科大学第四医院初诊并经胃镜/食管镜或转移灶活检证实为IVB期(依据UICC/AJCC第8版食管及食管胃结合部癌TNM分期)的原发胸段食管鳞癌患者199例。其中单纯远处淋巴结转移者130例（65.3%），仅锁骨

8、上淋巴结转移者121例；单纯实质脏器转移51例（25.6%）；实质脏器合并远处淋巴结转移者18例（9.0%）。采用单纯化疗16例（8.0%），单纯放疗50例（25.1%），放化综合治疗133例（66.8%），其中同期放化疗81例，序贯